Bio Pharma Dive
MAY 28, 2021
For decades, scientists have tried unsuccessfully to target the KRAS gene, which is often mutated in lung, colon and pancreatic cancers. Lumakras is the first drug proven effective.
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 27, 2024
The psychedelic drug psilocybin (as found in ‘magic’ mushrooms) has promising potential as a treatment for the eating disorder anorexia nervosa, according to new research that looked at its effects on an animal model of the condition.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MARCH 9, 2023
Prior trial failures hadn’t halted testing of solanezumab, once Lilly’s top Alzheimer’s drug candidate. But its final study defeat may help scientists better understand how to target the brain disease.
Pharmaceutical Technology
JULY 20, 2022
Gladstone Institute of Virology director Melanie Ott said: “It’s clear from our results that the BET drugs currently available are not suitable for Covid-19. But certain elements of these drugs could be adapted for future drug development.”.
Bio Pharma Dive
AUGUST 6, 2024
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
Pharmaceutical Technology
APRIL 11, 2023
Scientists at the Northwestern University in Illinois, US, have discovered a non-invasive approach to isolate a tumour’s attack cells from blood, rather than from tumours. Scientists removed and processed melanoma tumours, and found tumour-infiltrating lymphocytes (TILs) within them.
Bio Pharma Dive
SEPTEMBER 20, 2023
Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.
Expert insights. Personalized for you.
361 
Let's personalize your content